KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-cash Items (2016 - 2025)

Historic Non-cash Items for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $42.3 million.

  • CRISPR Therapeutics AG's Non-cash Items rose 20085.41% to $42.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $42.3 million, marking a year-over-year increase of 20085.41%. This contributed to the annual value of $42.3 million for FY2025, which is 20085.41% up from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Non-cash Items stood at $42.3 million for Q4 2025, which was up 20085.41% from $4.6 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's Non-cash Items' 5-year high stood at $219.1 million during Q4 2021, with a 5-year trough of $4.0 million in Q1 2021.
  • For the 5-year period, CRISPR Therapeutics AG's Non-cash Items averaged around $50.4 million, with its median value being $5.0 million (2025).
  • Its Non-cash Items has fluctuated over the past 5 years, first soared by 267543.7% in 2022, then tumbled by 9675.03% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Non-cash Items (Quarter) stood at $219.1 million in 2021, then tumbled by 85.34% to $32.1 million in 2022, then soared by 260.03% to $115.7 million in 2023, then crashed by 87.85% to $14.0 million in 2024, then skyrocketed by 200.85% to $42.3 million in 2025.
  • Its Non-cash Items stands at $42.3 million for Q4 2025, versus $4.6 million for Q3 2025 and $5.0 million for Q2 2025.